Post-Genomics
This article was originally published in Start Up
Executive Summary
With so much genomics data and putative drug targets to sift through, drug developers cannot risk making research resource allocation decisions before correlating gene and protein function with a disease process. The need has spawned a new generation of post-genomics companies focused on developing tools for validating drug targets, including smart screening methodologies and cell-based assays, and on ways to better organize and characterize genomics and proteomics data.